Adjuvant Therapy for Colorectal Cancer: Past Accomplishments, Future Directions

References

• Pauber S L, Tong T, Bolden S, et al. Cancer statistics 1996. CA Cancer J Clin 1996; 63: 5–27
   Google Scholar
• Cohen A M, Shank B, Friedman M A. Colorectal cancer. Cancer: Principles and Practice 3rd ed, V T Devila, Jr, S Hellman, S A Rosenberg. JB Lippincott, Philadelphia 1989; 929–977
   Google Scholar
• Dukes C E. The classification of cancer of the rectum. J Pathol Bacterid 1940; 50: 527–539
   Google Scholar
• Astler W B, Coller F A. The prognostic significance of direct extension of carcinoma of the colon and rectum. Ann Surg 1954; 139: 846–851
   PubMed Web of Science ®Google Scholar
• American Joint Committee on Cancer. Colon and rectum. Manual for Staging of Cancer, O Beahrs, D Henson, R Hutter, et al. JB Lippincott, Philadelphia 1988; 75–80
   Google Scholar
• Wolmark N, Fisher B, Wei H S. The prognostic value of the modification of the Dukes' C class of colorectal cancer: An analysis of the NSABP clinical trials. Ann Surg 1986; 203: 115–122
   PubMed Web of Science ®Google Scholar
• Willett C, Tepper J E, Cohen A, et al. Obstructive and perforative colonic carcinoma: Patterns of failure. J Clin Oncol 1985; 3: 379–384
   PubMed Web of Science ®Google Scholar
• Wanebo H J, Rao B, Pinsky C M, et al. Preoperative carcinoem-bryonic antigen level as a prognostic indicator in colorectal cancer. N Engl J Med 1978; 299: 448–451
   PubMed Web of Science ®Google Scholar
• Lo Gerfo P, Herter F. Carcinoembryonic antigen prognosis in patients with colorectal cancer. Ann Surg 1974; 181: 81–84
   Web of Science ®Google Scholar
• Wolmark N, Fisher B, Wieand S, et al. The prognostic significance of preoperative carcinoembryonic antigen levels in colorectal cancer. Ann Surg 1984; 199: 375–381
   PubMed Web of Science ®Google Scholar
• Steele G, Ellenberg S, Ramming K, et al. CEA monitoring among patients in multi-institutional adjuvant G.I. protocols. Ann Surg 1982; 196: 162–169
   PubMed Web of Science ®Google Scholar
• Moertel C G, O'Fallon J R, Go V LW, et al. The preoperative carcinoembryonic antigen test in the diagnosis, staging, and prognosis of colorectal cancer. Cancer 1986; 58: 603–610
   PubMed Web of Science ®Google Scholar
• Goslin R, Steele G, Maclntyre J, et al. The use of preoperative plasma CEA levels for the stratification of patients after curative resection of colorectal cancers. Ann Surg 1980; 192: 747–751
   PubMed Web of Science ®Google Scholar
• Scott N A, Wieand H S, Moertel C G, et al. Colorectal cancer: Dukes' stage, tumor site, preoperative plasma CEA level and patient prognosis related to tumor DNA ploidy pattern. Arch Surg 1987; 122: 1375–1379
   PubMed Web of Science ®Google Scholar
• Kokal W A, Gardine R L, Sheibani K, et al. Tumor DNA content in resectable, primary colorectal carcinoma. Ann Surg 1989; 209: 188–193
   PubMed Web of Science ®Google Scholar
• Albe X, Vassilakos P, Helfer-Guarnori K, et al. Independent prognostic value of ploidy in colorectal cancer. A prospective study using image cytometry. Cancer 1990; 66: 1168–1175
   PubMed Web of Science ®Google Scholar
• Sinicrope F, Hart J, Brasitus T, et al. Relationship of P-glycoprotein and carcinoembryonic antigen expression in human colon carcinoma to local invasion, DNA ploidy, and disease relapse. Cancer 1994; 74: 2908–2917
   PubMed Web of Science ®Google Scholar
• Moertel C G, Loprinzi C L, Witzig T E, et al. The dilemma of stage B2 colon cancer. Is adjuvant therapy justified? Proc Am Soc Clin Oncol 1990; 9: 108, (abstract)
   Google Scholar
• Johnston P G, Fisher E R, Rockette H E, et al. The role of thymidylate synthase expression in prognosis and outcome to adjuvant chemotherapy in patients with rectal cancer. J Clin Oncol 1994; 12: 2640–2647
   PubMed Web of Science ®Google Scholar
• Fisher B, Wolmark N, Rockette H, et al. Postoperative adjuvant chemotherapy or radiation therapy for rectal cancer: Results from NSABP protocol R-01. J Natl Cancer Inst 1988; 80: 21–29
   PubMed Web of Science ®Google Scholar
• Vogelstein B, Fearon E R, Hamilton S R, et al. Genetic alterations during colorectal-tumor development. N Engl J Med 1988; 319: 525–532
   PubMed Web of Science ®Google Scholar
• Zeng Z, Sarkis A, Zhang Z, et al. p53 nuclear expression: An independent predictor of survival in lymph node-positive colorectal cancer. J Clin Oncol 1994; 12: 2043–2050
   PubMed Web of Science ®Google Scholar
• Bosari S, Viale G, Bossi P, et al. Cytoplasmic accumulation of p53 protein: An independent prognostic indicator in colorectal adenocarcinomas. J Natl Cancer Inst 1994; 86: 681–687
   PubMed Web of Science ®Google Scholar
• Jen J, Kim H, Piantadosi S, et al. Allelic loss of chromosome 18q and prognosis in colorectal cancer. N Engl J Med 1994; 331: 213–221
   PubMed Web of Science ®Google Scholar
• Cass A W, Million R R, Pfaff W W. Patterns of recurrence following surgery alone for adenocarcinoma of the colon and rectum. Cancer 1976; 37: 2861–2865
   PubMed Web of Science ®Google Scholar
• Pilipsen S J, Hielweil M, Quan S HQ, et al. Patterns of pelvic recurrence following definitive resections of colorectal cancer. Cancer 1984; 53: 1354–1362
   PubMed Web of Science ®Google Scholar
• Rao A R, Kagan A R, Chan P M, et al. Patterns of recurrence following curative resection alone for adenocarcinoma of the rectum and sigmoid colon. Cancer 1981; 48: 1492–1495
   PubMed Web of Science ®Google Scholar
• Rich T, Gunderson L L, Lew R, et al. Patterns of recurrence of colorectal cancer after potentially curative surgery. Cancer 1983; 52: 1317–1329
   PubMed Web of Science ®Google Scholar
• Gunderson L, Sosin H. Areas of failure found at reoperation following curative surgery for adenocarcinoma of the rectum. Clinicopathologic correlation and implications for adjuvant therapy. Cancer 1974; 34: 1278–1292
   PubMed Web of Science ®Google Scholar
• Mendenhall M W, Million R R, Pfaff W W. Patterns of recurrence in adenocarcinoma of the rectum and rectosigmoid treated with surgery alone: Implications in treatment planning with adjuvant radiation therapy. Int J Radiat Oncol 1983; 9: 977–985
   PubMed Web of Science ®Google Scholar
• Pihl E, Hughes S, McDermott F, et al. Disease-free survival and recurrence after resection of colorectal carcinoma. J Surg Oncol 1981; 16: 333–341
   PubMed Web of Science ®Google Scholar
• Willet C G, Tepper J E, Chen A M, et al. Failure patterns following curative resection of colorectal carcinoma. Ann Surg 1984; 200: 685–690
   PubMed Web of Science ®Google Scholar
• Russell A, Toiig D, Dawson L, et al. Adenocarcinoma of the proximal colon. Sites of initial dissemination and patterns of recurrence following surgery alone. Cancer 1984; 53: 360–367
   PubMed Web of Science ®Google Scholar
• Wolmark N, Fisher B, Rockette H, et al. Postoperative adjuvant chemotherapy or BCG for colon cancer: Results from NSABP protocol C-01. J Natl Cancer Inst 1988; 80: 30–36
   PubMed Web of Science ®Google Scholar
• Marangolo M, Pezzuoli G, Marubini E, et al. Adjuvant chemotherapy with fluorouracil and CCNU in colon cancer. Tumori 1989; 75: 269–276
   PubMed Web of Science ®Google Scholar
• Buyse M, Zeleniuch-Jaquitte A, Chalmers T. Adjuvant therapy of colorectal cancer—Why we still don't know. JAMA 1988; 259: 3571–3578
   PubMed Web of Science ®Google Scholar
• Stevenson H C, Green I, Hamilton J M, et al. Levamisole: Known effects on the immune system, clinical results and future applications to the treatment of cancer. J Clin Oncol 1991; 9: 2052–2066
   PubMed Web of Science ®Google Scholar
• Verhaegen H, Decree J, Decock W. Levamisole therapy in patients with colorectal cancer. Immunotherapy of Human Cancer, W Terry, S Rosenberg. Elsevier, New York 1982; 225–229
   Google Scholar
• Abdauah E A, Blair G E, Jones R A, et al. Mechanism of synergy of levamisole and 5-FU: Induction of human leukocyte antigen class 1 in colorectal cancer cell line. J Natl Cancer Inst 1995; 87: 489–496
   PubMed Web of Science ®Google Scholar
• Davis T, Borden E, Wolberl W, et al. Levamisole and 5-FU in metastatic colorectal carcinoma. Proc Am Soc Clin Oncol 1982; 1: 10
   Google Scholar
• Buroker T, Moertel C, Fleming T, et al. A controlled evaluation of recent approaches to biochemical modulation or enhancement of 5-FU therapy in colorectal carcinoma. J Clin Oncol 1985; 3: 1624–1631
   PubMed Web of Science ®Google Scholar
• Mansour E G, Cnaan A, Davis T, et al. Combined modality therapy following resection of colorectal carcinoma in patients with non-measurable intra-abdominal metastases. An ECOG study 3282. Proc Am Soc Clin Oncol 1990; 412: 107, (abstract)
   Google Scholar
• Chlebowski R T, Nystrom S, Reynold R, et al. Long term survival following levamisole or placebo adjuvant treatment of colorectal cancer: A Western Oncology Group trial. Oncology 1988; 45: 141–143
   PubMed Web of Science ®Google Scholar
• Arnaud J B, Buyse M, Norlinger B, et al. Adjuvant therapy of poor prognosis colon cancer with levamisole: Results of an EORTC double-blinded randomized clinical trial. Br J Surg 1989; 76: 284–289
   PubMed Web of Science ®Google Scholar
• Laurie J A, Moertel C G, Fleming T R, et al. Surgical adjuvant therapy of large-bowel cancer: An evaluation of levamisole and the combination of levamisole and 5-FU. J Clin Oncol 1989; 7: 1447–1456
   PubMed Web of Science ®Google Scholar
• Moertel C G, Fleming T R, Macdonald J S, et al. Levamisole and 5-FU for adjuvant therapy of resected colon cancer. N Engl J Med 1990; 322: 352–358
   PubMed Web of Science ®Google Scholar
• Moertel C G, Fleming T R, Macdonald J S, et al. 5-FU plus levamisole as effective adjuvant therapy after resection of stage III colon carcinoma: A final report. Ann Intern Med 1995; 122: 321–326
   PubMed Web of Science ®Google Scholar
• Anonymous: The efficacy of the group C status of levamisole and 5-FU for patients with Dukes' C colon cancer. National Cancer Institute Update. October, 1989
   Google Scholar
• Hook C, Kimmel D, Krolls L. Multifocal leukoencephalopathy: With 5-FU and levamisole. Ann Neurol 1992; 31: 262–267
   PubMed Web of Science ®Google Scholar
• Moertel C G, Fleming T R, Macdonald J S. Hepatic toxicity associated with 5-FU plus levamisole in adjuvant therapy. J Clin Oncol 1993; 11: 2386–2390
   PubMed Web of Science ®Google Scholar
• Moertel C G, Fleming T R, Macdonald J S, et al. Intergroup study of fluorouracil plus levamisole as adjuvant therapy for stage II/Dukes' B2 colon cancer. J Clin Oncol 1995; 13: 2936–2943
   PubMed Web of Science ®Google Scholar
• Rustum Y M. Modulation of fluoropyrimidines by leucovorin: Rationale and status. J Surg Oncol 1991, Suppl 2: 116–123
   Google Scholar
• Peon M A, O'Connell M J, Wieand H S, et al. Biochemical modulation of fluorouracil with leucovorin: Confirmatory evidence of improved therapeutic efficacy in advanced colorectal cancer. J Clin Oncol 1991; 9: 1967–1972
   PubMed Web of Science ®Google Scholar
• Piedbois P, Buyse M, Rustum Y, et al. Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: Evidence in terms of response rate. By the Advanced Colorectal Cancer Meta-Analysis Project. J Clin Oncol 1992; 10: 896–903
   PubMed Web of Science ®Google Scholar
• Wolmark N, Rockette H, Fisher B, et al. The benefit of leucovorin-modulated fluorouracil as postoperative adjuvant therapy for primary colon cancer: Results from National Surgical Adjuvant Breast and Bowel Project Protocol C-03. J Clin Oncol 1993; 11: 1879–1887
   PubMed Web of Science ®Google Scholar
• International Multicenter Pooled Analysis of Colon Cancer Trials (IMPACT) Investigators. Efficacy of adjuvant fluorouracil and folinic acid in colon cancer. Lancet 1995; 345: 939–944
   PubMed Web of Science ®Google Scholar
• Buroker T R, O'Connell M J, Wieand S, et al. Randomized comparison of two schedules of fluorouracil and leucovorin in the treatment of advanced colorectal cancer. J Clin Oncol 1994; 12: 14–20
   PubMed Web of Science ®Google Scholar
• Haller D G, Catalano D J, Macdonald J S, et al. Fluorouracil (PU), leucovorin (LV) and levamisole (lev) adjuvant therapy for colon cancer: Preliminary results of INT-0089. Proc Am Soc Clin Oncol 1996; 15: 211
   Google Scholar
• Wolmark N, Rochette H, Mainounas E P, et al. The relative efficacy of 5-FU and leucovorin (FU-LU), 5-FU and levamisole (FU-Lev), and 5-FU + leucovorin and levamisole (FU-LV-lev) inpatients with Dukes' B and C carcinoma of the colon: First report of NSABP C-04. Proc Am Soc Clin Oncol 1996; 15: 205
   Google Scholar
• Grem J L, Jordan E, Robson M E, et al. Phase II study of fluorouracil, leucovorin, and interferon alfa-2a in metastatic colorectal carcinoma. J Clin Oncol 1993; 11: 1737–1745
   PubMed Web of Science ®Google Scholar
• Anderson N, Lokich J J. Cancer chemotherapy and infusional scheduling. Oncology 1994; 8: 99–116
   PubMedGoogle Scholar
• Sorenson J M, Jordon E, Green J L, et al. Phase I trial of ZD1694: A pure thymidylate synthase inhibitor. Proc Am Soc Clin Oncol 1993; 12: 158
   Google Scholar
• Cunningham D, Zalcberg J, Francois E, et al. Tomudex (ZD1694) a new thymidylate synthase inhibitor with good antitumor activity in advanced colorectal cancer (ACC). Proc Am Soc Clin Oncol 1994; 13: 199
   Google Scholar
• Shimada Y, Yoshino M, Wakui A, et al. Phase II study of CPT-11, a new camphothecin derivative, in metastatic colorectal cancer. J Clin Oncol 1993; 11: 909–913
   PubMed Web of Science ®Google Scholar
• Rothenberg M L, Echardt J R, Burns H A, III, et al. Irinotecan (CPT-11) as second-line therapy for patients with 5-FU refractory colorectal cancer. Proc Am Soc Clin Oncol 1994; 13: 198
   Google Scholar
• Shimada Y, Sasaki Y, Sugano K, et al. Combination phase I study of CPT-11 (irinotecan) combined with continuous infusion of 5-fluorouracil (5-FU) in metastatic colorectal cancer. Proc Am Soc Clin Oncol 1993; 12: 196
   Google Scholar
• Taylor I, Machint D, Mulleet M, et al. A randomized controlled trial of adjuvant portal vein cytotoxic perfusion in colorectal cancer. Br J Surg 1985; 72: 359–363
   PubMed Web of Science ®Google Scholar
• Wolmark N, Rockette H, Wickerman D L, et al. Adjuvant therapy of Dukes' A, B, and C adenocarcinoma of the colon with portal-vein fluorouracil hepatic infusion: Preliminary results of National Surgical Adjuvant Breast and Bowel Project Protocol C-02. J Clin Oncol 1990; 8: 1466–1475
   PubMed Web of Science ®Google Scholar
• Wolmark N, Rockette H, Petrelli N, et al. Long-term results of the efficacy of perioperative portal vein infusion of 5-FU for treatment of colon cancer: NSABP C-02. Proc Am Soc Clin Oncol 1994; 13: 194
   Google Scholar
• Picdbois P, Buyse M, Gray R, et al. Portal vein infusion is an effective adjuvant treatment for patients with colorectal cancer. Proc Am Soc Clin Oncol 1995; 14: 192
   Google Scholar
• Hoover H C, Jr, Brandhorst J S, Peters L C, et al. Adjuvant active specific immunotherapy for human colorectal cancer: 6.5-year median follow-up of a phase III prospectively randomized trial. J Clin Oncol 1993; 11: 390–399
   PubMed Web of Science ®Google Scholar
• Moertel C G. Editorial, Vaccine adjuvant therapy for colorectal cancer: “Very dramatic” or “ho-hum.”. J Clin Oncol 1993; 11: 386–395
   Google Scholar
• Mellstedt H, Frodin J E, Masucci G, et al. The therapeutic use of monoclonal antibodies in colorectal carcinoma. Semin Oncol 1991; 2: 462–477
   Google Scholar
• Lobuglio A F, Saleh M N, Lee J, et al. Phase I trial of multiple large doses of murine monoclonal antibody C017–1A. I. Clinical aspects. I Natl Cancer Inst 1988; 80: 932–936
   PubMed Web of Science ®Google Scholar
• Riethmuller G, Schneider-Gadicke E, Schlimok G, et al. Randomised trial of monoclonal antibody for adjuvant therapy of resected Dukes' C colorectal carcinoma. Lancet 1994; 343: 1177–1183
   PubMed Web of Science ®Google Scholar
• Gerard A, Buyse M, Nordlinger B, et al. Preoperative radiotherapy as adjuvant treatment in rectal cancer. Final results of a randomized study of the European Organization for Research and Treatment of Cancer. Ann Surg 1988; 208: 606–614
   PubMed Web of Science ®Google Scholar
• Higgins G A, Humphrey E W, Dwight R W, et al. Preoperative radiation and surgery for cancer of the rectum. Veterans Administration Surgical Oncology Group Trial II. Cancer 1986; 58: 352–359
   PubMed Web of Science ®Google Scholar
• Bentzen S M, Balstev I, Penderson M, et al. A regression analysis of prognostic factors after resection of Dukes' B and C carcinoma of the rectum and rectosigmoid. Does postoperative radiotherapy change the prognosis? Br J Cancer 1988; 58: 195–201
   Google Scholar
• Vokes E, Weichseibaum R. Concomitant chemoradiotherapy: rationale and clinical experience in patients with solid tumors. J Clin Oncol 1990; 8: 911–920
   PubMed Web of Science ®Google Scholar
• Gastrointestinal Tumor Study Group. Prolongation of the disease-free interval in surgically treated rectal carcinoma. N Engl J Med 1985; 312: 1465–1472
   PubMed Web of Science ®Google Scholar
• Gastrointestinal Tumor Study Group. Survival after postoperative combination treatment of rectal carcinoma. N Engl J Med 1986; 315: 1294–1295
   PubMed Web of Science ®Google Scholar
• Krook J E, Moertel C G, Gunderson L L, et al. Effective surgical adjuvant therapy for high-risk rectal carcinoma. N Engl J Med 1991; 324: 709–715
   PubMed Web of Science ®Google Scholar
• Gastrointestinal Tumor Study Group. Radiation therapy and 5-FU with or without semustine for the treatment of patients with surgical adjuvant adenocarcinoma of the rectum. J Clin Oncol 1992; 10: 549–557
   PubMed Web of Science ®Google Scholar
• O'Connell M J, Martenson J A, Wieand H S, et al. Improving adjuvant therapy for rectal cancer by combining protracted-infusion 5-FU with radiation therapy after curative surgery. N Engl J Med 1994; 331: 502–507
   PubMed Web of Science ®Google Scholar
• Rockette H I, Deutsch M, Petrelli N. Effect of postoperative radiation therapy (RTX) when used with adjuvant chemotherapy in Dukes' B and C rectal cancer: Results from NSABP R-02. Proc Am Soc Clin Oncol 1994; 13: 193
   Google Scholar
• Minsky B D. Preoperative combined modality treatment for colorectal cancer. Oncology 1994; 8: 53–68
   PubMedGoogle Scholar
• Tempero M, Buard R, Holdemank, et al. New imaging techniques in colorectal cancer. Semin Oncol 1995; 22: 448–471
   PubMed Web of Science ®Google Scholar
• Willett C G, Tepper J E, Shellito P C, et al. Indications for adjuvant radiotherapy in extrapelvic colonic carcinoma. Oncology 1989; 3: 25–32
   PubMedGoogle Scholar